British melanoma patients will be the first in Europe to receive a new drug cocktail combining two immunotherapy treatments, following an unusually rapid approval by the country’s healthcare cost agency NICE on Friday.
The National Institute for Health and Care Excellence (NICE), which decides if therapies are worth using on the state health service, is more often in the news for delaying or refusing access to pricey modern cancer drugs.
Source: Reuters
Filed Under: Drug Discovery
